- Home
- CVV vs NXTC Comparison
CVV vs NXTC Comparison
Compare CVV & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVV
- NXTC
- Stock Information
- Founded
- CVV 1982
- NXTC 2015
- Country
- CVV United States
- NXTC United States
- Employees
- CVV N/A
- NXTC N/A
- Industry
- CVV Industrial Machinery/Components
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- CVV Technology
- NXTC Health Care
- Exchange
- CVV Nasdaq
- NXTC Nasdaq
- Market Cap
- CVV 23.5M
- NXTC 23.0M
- IPO Year
- CVV N/A
- NXTC 2019
- Fundamental
- Price
- CVV $3.50
- NXTC $0.77
- Analyst Decision
- CVV
- NXTC Strong Buy
- Analyst Count
- CVV 0
- NXTC 2
- Target Price
- CVV N/A
- NXTC $4.00
- AVG Volume (30 Days)
- CVV 31.8K
- NXTC 117.3K
- Earning Date
- CVV 03-27-2025
- NXTC 03-20-2025
- Dividend Yield
- CVV N/A
- NXTC N/A
- EPS Growth
- CVV N/A
- NXTC N/A
- EPS
- CVV N/A
- NXTC N/A
- Revenue
- CVV $23,573,000.00
- NXTC N/A
- Revenue This Year
- CVV N/A
- NXTC N/A
- Revenue Next Year
- CVV N/A
- NXTC N/A
- P/E Ratio
- CVV N/A
- NXTC N/A
- Revenue Growth
- CVV N/A
- NXTC N/A
- 52 Week Low
- CVV $2.70
- NXTC $0.76
- 52 Week High
- CVV $6.35
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- CVV 44.36
- NXTC 39.76
- Support Level
- CVV $3.33
- NXTC $0.76
- Resistance Level
- CVV $3.69
- NXTC $0.90
- Average True Range (ATR)
- CVV 0.20
- NXTC 0.06
- MACD
- CVV -0.02
- NXTC 0.01
- Stochastic Oscillator
- CVV 33.93
- NXTC 19.58
About CVV CVD Equipment Corporation
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.